The value of adenosine deaminase level in assessing activation of inflammatory bowel disease

• Main Authors: Züleyha Akkan Çetinkaya, Yasemin Gökden, Semih Kalyon, Semih Hot, Can Gönen
• Format: Article
• Language: English
• Published: Journal of Surgery and Medicine 2020-08-01
• Series: Journal of Surgery and Medicine
• Subjects: ulcerative colitis; crohn’s disease; adenosine deaminase; crohn hastalığı; ülseratif kolit; adenozin deaminaz
• Online Access: https://dergipark.org.tr/en/pub/josam/issue/56401/769877
• ISSN: 2602-2079

Aim: There is still a need for an ideal laboratory test that can determine the type of disease, the degree of its activity, predict its course, and monitor treatment response in patients with inflammatory bowel disease (IBD). This study aims to investigate the relationship between disease types and activity with Adenosine deaminase (ADA) levels in patients with IBD. Methods: A total of 92 patients with IBD [43 with Crohn’s disease (CD) and 49 with ulcerative colitis (UC)] and 31 healthy control (HC) volunteers were included in this case-control study. Patients’ age, gender, body mass index, location and severity of the disease, medication, endoscopic examination, hemogram, C-reactive Protein (CRP), and ADA results were evaluated. Results: The mean ADA level was 24.87 (9.6 - 74.9) IU/L in the IBD group and 20.8 (13.7 - 38.9) IU/L in the HC group. The difference between the IBD and HC groups was statistically significant (P